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Chemical geneticsNumerous studies show that pharmacological inhibition of p38 mitogen-activated protein kinases (p38s)
before lethal ischemia prevents conditioning. However, these inhibitors have off-target effects and do not
discriminate between the alpha and beta isoforms; the activation of which is thought to have diverse and
perhaps opposing actions with p38α aggravating, and p38β reducing, myocardial injury. We adopted a
chemical genetic approach using mice in which either the p38α (DRα) or p38β (DRβ) alleles were targeted
to substitute the “gatekeeper” threonine residue for methionine, thereby preventing the binding of a
pharmacological inhibitor, SB203580. Isolated, perfused wild-type (WT), DRα and DRβ mouse hearts
underwent ischemic preconditioning with 4 cycles of 4 min ischemia/6 min reperfusion, with or without
SB203580 (10 µM), followed by 30 min of global ischemia and 120 min of reperfusion. In WT and DRβ hearts,
SB203580 completely abolished the reduction in myocardial infarction seen with preconditioning and also
the phosphorylation of downstream substrates of p38. These effects of SB203580 were not seen in DRα
hearts. Furthermore ischemic preconditioning occurred unaltered in p38β null hearts. Contrary to
expectation the activation of p38α, and not p38β, is necessary for ischemic preconditioning. Since p38α is
also the isoform that leads to lethal myocardial injury, it is unlikely that targeted therapeutic strategies to
achieve isoform-selective inhibition will only prevent the harmful consequences of activation.ial infarction as a percentage of
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The heart is a dynamic organ that must respond and adapt to a
variety of stresses throughout life. These adaptations are achieved
through numerous signaling pathways of which the aptly named
stress-activated protein kinases (SAPKs) are amongst the most
evolutionarily conserved. The SAPKs consist of the Jun N-terminal
kinases and the p38 mitogen-activated protein kinases (p38s). The
p38s in turn comprise 4 family members, encoded by separate genes,
p38α, p38β, p38γ and p38δ [1]. There are considerable data
suggesting that inhibition of p38s during lethal ischemia is cardio-
protective whilst under identical conditions the same inhibitors can
block the protection seen with ischemic preconditioning [2]. Thepharmacological inhibitors used in these studies, such as SB203580,
only affect the p38α and p38β isoforms since their selectivity relies on
their probing of a “hole” at the edge of the ATP-binding pocket
guarded by a “gatekeeper” threonine residue (106 in murine and
human p38α and p38β) [3,4]. In p38γ and p38δ this position is
occupied by amore bulkymethionine residue that prevents binding of
the inhibitor and therefore its competition with ATP. By substituting
threonine 106 for methionine (T106M), p38α and p38β can be
rendered similarly resistant to pharmacological inhibition without
altering kinase activity [4]. SB203580 is a frequently used cell-
permeate pharmacological inhibitor with a rapid onset and offset of
action but it is not selective and known to inhibit a number of other
kinases [5]. Using the T106M knock-in mice, we are able to
discriminate between the on and off-target effects of this inhibitor.
The reason remains uncertain why pharmacological inhibition of
p38α and p38β should result in protection during lethal ischemia and
the prevention of ischemic preconditioning before lethal ischemia.
However, the favored explanation is that p38α is the dominant
isoform activated during lethal ischemia, and its activation aggravates
injury; whilst p38β is the dominant isoform activated during the
sublethal ischemia/reperfusion of preconditioning, and its activation
diminishes injury [6–8]. Deﬁning the exact contribution of these
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important since it may enhance the magnitude of beneﬁt in planned
and ongoing (NCT00910962) clinical trials in myocardial infarction.
A number of studies that do not rely on pharmacological inhibitors
suggest that p38α aggravates lethal injury [3,9,10]. Therefore, our
hypothesis was that p38β is the isoform responsible for inhibitors
blocking preconditioning.
2. Materials and methods
2.1. Mice
All experiments were performed in accordance with United
Kingdom Home Ofﬁce Guidance on the Operation of Animals (Scientiﬁc
Procedures) Act 1986, published by Her Majesty's Stationary Ofﬁce,
London.
The knock-in mice harboring a T106M substitution in p38α (Drug-
Resistant, DRα), or in p38β (DRβ), were on an isogenic C57BL/6
background shared with their corresponding wild type mice (B6) and
have been described previously [11]. The knock-out mice for p38β
(p38βKO) that were on a C57BL/6 background resulting from
backcrossing for at least 10 generations have also been described
previously [12] and were compared with their corresponding wild
type mice (WT).
2.2. Perfusion of isolated murine hearts
Adultmalemicewere anesthetizedwith pentobarbital (300 mg/kg)
and heparin (150 U) intraperitoneally. Hearts were rapidly isolated,
mounted onto a Langendorff apparatus and retrogradely perfused at a
constant pressure of 80 mmHgwith Krebs–Hensleit buffer (inmmol/L:
118.5 NaCl, NaHCO3, 4.75 KCl, 0.18 KH2PO4, 1.19MgSO4, 11.0 D-glucose,
and 1.41 CaCl2) equilibrated with 95% O2 and 5% CO2 at 37 °C. A ﬂuid-
ﬁlled balloon inserted into the left ventricular cavity monitored
contractile function. The balloon was gradually inﬂated until the left
ventricular end-diastolic pressure (LVEDP) was between 2 and
8 mmHg. Atrial pacing was performed at 580 bpm and coronary ﬂow
(CF) was measured by timed collection of perfusate.
2.3. Infarction assessment in isolated murine hearts
Hearts were stabilized for 50 min after initiation of retrograde
perfusion. For inclusion, all hearts had to fulﬁll the following criteria:
CF between 1.5 and 4.5 mL/min, initial heart rateN300 bpm
(unpaced), left ventricular developed pressure (LVDP)N55 mm Hg,
time from thoracotomy to aortic cannulationb3 min, and no persis-
tent dysrhythmias during the stabilization period. All hearts under-
went 30 min of global ischemia followed by 2 h of reperfusion. At the
end of reperfusion hearts were perfused for 1 min with 5 mL of 1%
triphenyl tetrazolium chloride (TTC) in PBS and then placed in an
identical solution at 37 °C for 10 min. The atria were then removed,
and the hearts were blotted dry, weighed, and stored at −20 °C.
Hearts were subsequently thawed, placed in 2.5% glutaraldehyde for
1 min and set in 5% agarose. The agarose heart blocks were then
sectioned from apex to base in 0.75 mm slices using a vibratome (Agar
Scientiﬁc). Sections were compressed between glass plates and scan-
imaged (Epson model G850A). After magniﬁcation, planimetry was
carried out using image analysis software (Adobe Photoshop 7.0). Risk
and infarct volumes were calculated from surface area analysis of
whole myocardium and TTC-negative myocardium, respectively,
multiplied by tissue thickness. After summation of individual slices,
infarct volume was expressed as a percentage of ventricular volume.
Infarct analysis was performed in all cases by an investigator blinded
to the group assignments.
The experimental protocol appears as in Fig. 1(A).2.4. Immunoblotting
Samples were thawed and homogenized in protein extraction
buffer (50 mmol/L Tris–HCl; pH 7.5, 1 mmol/L EDTA, 1 mmol/L EGTA,
1% (w/v) Triton X-100, 0.1% β-mercaptoethanol, 1 mmol/L sodium
orthovanadate, 50 mmol/L sodium ﬂuoride, 5 mmol/L sodium pyro-
phosphate and protease inhibitor tablets (Complete®, Roche Applied
Science), (1 Tab/50 mL of buffer)). One millilitre of extraction buffer
was used per 100 mg of frozen tissue. Homogenates were centrifuged
at 4 °C for 10 min at 13,000 rpm and the insoluble fraction discarded.
Protein content was estimated using a Bio-Rad Protein Assay Kit.
Twenty micrograms of protein was electrophoresed on a 10%
polyacrylamide gel and then blotted onto a polyvinylidene diﬂuoride
membrane.
PVDF membranes which were blocked for 2 h with 5% non-fat
milk+1%BSA in TRIS-buffered saline (pH 7.4) containing 0.1% Triton
(TBST) and probed overnight at 4 °C with the appropriate primary
antibody recognizing total-p38 (#9212) (Tp38), diphospho-p38 (#9211,
polyclonal) (pp38) or phospho-HSP27 (#2401) all fromCell Signaling, or
to phospho-TAB1(S423) from Sir Philip Cohen (Dundee UK). After
washing and exposure for 2 h at room temperature to HRP-conjugated
secondary antibody, antibody–antigen complexes were visualized by
enhanced chemiluminescence as previously described [13].
2.5. Statistics
Data sets were analyzed by two-way ANOVA and groups were
compared using Tukey's test. A P value less than 0.05 was considered
signiﬁcant.
3. Results and discussion
In this study, we tested the hypothesis that p38β is the isoform
responsible for the loss of preconditioning with pharmacological
inhibitors that do not discriminate between isoforms (Fig. 1(A)). In
order to examine this question, we used DRα and DRβmice in which
the substitution of threonine 106 for methionine renders p38α or
p38β resistant to pharmacological inhibition without altering kinase
activity.
Baseline coronary ﬂow and contractile parameters were similar at
the end of stabilization across mouse hearts of all genotypes (Table 1).
In B6/WT hearts preconditioning resulted in signiﬁcant improve-
ments in post-ischemic hemodynamic recovery that reﬂected infarct
size (Table 1 and Fig. 1(B)). Exposure to SB203580 during precondi-
tioning cycles completely abolished its beneﬁt in B6 and in DRβ mice
(I/R% 32.1% vs. 46.4%, Pb0.05 and 31.0% vs. 49.8%, respectively,
Pb0.01, Fig. 1(B)) in which p38α, but not p38β, was sensitive to
inhibition. However, SB203580 failed to prevent preconditioning in
the DRα mice (I/R% 29.6 vs. 26.6%, PN0.05, Fig. 1(B)) in which p38β,
but not p38α, was sensitive to inhibition. These differential effects of
SB203580 by genotype were mirrored in post-ischemic contractile
recovery (Table 1).
In order to conﬁrm that ischemic preconditioning occurred
independently of p38βwe subjected βKOmouse hearts to an identical
protocol. Baseline coronary ﬂow and contractility were similar at the
end of the stabilization period in all groups (Table 1). Preconditioning
similarly improved hemodynamic recovery (Table 1) and reduced
infarct size (Fig. 1(C)) inWT hearts with, and p38βKO hearts without,
p38β. Taken together with the results in the drug-resistant mouse
hearts, the ﬁndings indicate that ischemic preconditioning is
dependent on the activation of p38α, but not of p38β.
We next examined the effects of SB203580 on downstream
signaling (Figs. 1(D)–(F)) by investigating the intensity of the dual
phosphorylation of p38 as well as the phosphorylation of the
downstream substrates TAB1 and HSP27 on Ser423 and Ser82,
respectively which likely reﬂects the transient activation of p38 in
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HSP27 are both sensitive to SB203580 in WT and DRβ hearts (Figs. 1
(D), (F)) but become resistant in DRα hearts, reﬂecting the
dominance of this isoform during preconditioning and its resistance
to inhibition by SB203580 (Fig. 1(E)).Thus, themajor ﬁnding in this study is that contrary to expectation
the activation of p38α and not p38β is necessary for ischemic
preconditioning. This conclusion is based both on a chemical-genetic
approach using targeted mouse-lines with a single amino-acid
substitution in p38α or p38β and is corroborated in p38β-null mice.
Table 1
Baseline characteristics and hemodynamic recovery in drug resistant p38α (DRα) and p38β (DRβ) mice and their corresponding wild-type (B6) and in p38β null mice (p38β KO)
and their corresponding wild-type (WT).
Treatment n Body
weight (g)
LVDP (mm Hg) LVEDP (mm Hg) CF (mL/min)
Baseline 60 min Rep 120 min Rep Baseline 60 min Rep 120 min Rep Baseline 60 min Rep 120 min Rep
B6 6 28.6±1.0 69.8±5.7 6.5±3.4 8.2±4.7 6.2±2.9 68.7±10.6 62.4±10.5 2.6±0.3 1.5±0.3 1.2±0.5
B6 PC 7 27.9±1.2 65.1±6.3 15.2±8.3⁎,† 18.5±5.6⁎,† 5.3±2.8 55.6±10.9⁎ 47.6±10.5⁎ 2.3±0.3 1.7±0.4 1.5±0.5
B6 PC+SB 7 26.8±1.7 62.3±7.2 3.6±3.2 5.5±2.9 7.6±2.7 63.3±10.2 56.3±8.6 2.8±0.4 1.7±0.4 1.4±0.6
B6 SB WO 6 24.3±2.4 63.6±5.4 3.3±3.6 4.8±3.6 5.3±3.7 61.8±6.7 55.8±6.7 2.9±0.3 1.3±0.2 1.2±0.3
DR α 6 25.9±1.5 67.5±6.5 5.8±4.7 6.0±4.5 4.8±2.2 65±6.2 58.1±9.8 2.4±0.2 1.2±0.4 1.0±0.3
DR α PC 6 25.1±1.3 62.2±5.9 16.8±7.1‡ 17.6±4.7 5.1±2.0 54.3±8.8 47.5±5.8‡ 2.3±0.3 1.6±0.4 1.5±0.5
DR α PC+SB 7 25.1±1.5 62.5±3.8 14.2±6.5§ 15.1±4.7 6.7±3.3 57.5±8.1 50.5±8.2§ 2.7±0.5 1.7±0.3 1.5±0.6
DR β 6 27.6±1.2 68.5±5.7 4.1±2.3 2.3±3.5 5.6±1.6 67.6±12.7 59.3±10.6 2.7±0.4 1.4±0.4 1.3±0.6
DR β PC 6 24.9±1.0 62.1±5.8 12.7±7.9||,# 13.8±7.8||,# 4.5±1.9 54.2±14.5||,# 46.7±13.0 2.6±0.4 1.8±0.4 1.7±0.5
DR β PC+SB 6 25.9±1.2 65.1±3.0 3.2±3.1 3.3±2.7 7.9±1.8 65.8±10.7 56.3±10.5 3.0±0.5 1.8±0.6 1.5±0.6
WT 7 29.9±0.6 71.0±11.1 15.5±6.7 18.3±6.8 7.8±1.1 54.3±13.1 47.3±14.5 3.8±0.9 2.0±0.6 1.5±0.5
WT PC 7 29.3±0.5 69.9±10.9 26.5±13.1⁎⁎ 36.7±13.6⁎⁎ 8.6±2.8 33.6±11.6 27.7±6.6⁎⁎ 3.2±0.8 2.2±0.7 2.3±0.8⁎⁎
p38 β KO 6 30.5±0.8 71.4±8.6 21.7±7.2 20.1±9.6 6.8±1.3 50.2±17.7 45.1±13.8 3.7±0.6 2.2±0.6 1.8±0.8
p38 β KO PC 7 28.4±0.6 75.9±6.6 18.6±10.5 31.3±9.2†† 6.7±4.9 45.8±22.1 34.3±18.9 3.5±0.4 2.5±2.1 2.4±1.3
Values are means±SEM. ⁎Pb0.05 B6 PC vs. B6, †Pb0.05 B6 PC vs. B6 PC+SB, ‡Pb0.05 DRα PC vs. DRα, §Pb0.05 DRα PC+SB vs. DRα, ||Pb0.05 DRβ PC vs. DR β, #Pb0.05 DR β PC vs.
DR β PC+SB; ⁎⁎Pb0.05 WT PC vs. WT; ††Pb0.05 p38 β KO PC vs. p38 β KO.
Left ventricular developed pressure (LVDP), left ventricular end-diastolic pressure (LVEDP) and coronary ﬂow (CF) were measured after 30 min of stabilization (Baseline), and at
60 min (Rep 60 min) and 120 min (Rep 120 min) after the onset of reperfusion.
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activation of p38α with cardioprotection. Furthermore, it is also one
of the ﬁrst examples of in-vivo murine chemical-genetics applied to a
cardiovascular phenotype and circumvents many of the disadvan-
tages that cloud data interpretation in transgenic mouse models [14].
Our ﬁndings are surprising since detrimental consequences of
p38α activation are supported by studies that do not simply rely on
pharmacological inhibition or ectopic overexpression of a wild-type
isoform. For example, the protective effect of SB203580 on isolated
cardiomyocytes exposed to lethal simulated ischemia is lost with
expression of p38α resistant to pharmacological inhibition [3].
Similarly, mice heterozygous for a p38α null allele, leading to reduced
protein content [10], are resistant to infarction as are mice transgenic
for a kinase dead form of p38α [9]. Thus there is strong direct
evidence that the activation of p38α during lethal ischemia increases
injury. However, recent studies in conditional cardiac-speciﬁc p38α
null mice subjected to pressure overload similarly suggest that this
isoform can play an unexpected protective role [15].
There are several reasons why under some circumstances the
activation of a single isoform of p38 can lead to reduced, and under
others increased, injury, including the timing of activation, differential
localization and perhaps most importantly different modes of
activation [1]. Instead of the classical MAPKKK–MAPKK–MAPK
canonical activation cascade, p38α is also known to auto-activate
through at least 2 mechanisms one dependent on the kinase ZAP-70,
and the other the scaffold protein TAB-1 [1,16]. In the later case at
least this seems relevant to ischemia and may antagonise the
canonical pathway [1].
Although it would be interesting to replicate the protocol in an in-
vivo model this is impractical since it is essential to washout the p38
inhibitor prior to lethal ischemia in order to ensure data interpreta-
tion is not clouded by the direct, but separate, cardioprotective effects
of these compounds during sustained ischemia [1].Fig. 1. Experimental protocol and infarct sizes. Panel (A) All hearts were subjected to 50 min
global ischemia with 6 min of reperfusion with blinding to corresponding vehicle (DMSO 0
washed out during the last reperfusion. After 120 min of reperfusion the infarct size was dete
preconditioning ischemia. Panels (B) and (C) Infarct size is expressed as percent of the left ve
which the data are based appears as the numeral inset in the bar labels. The “+” and “−” sign
Panels (D), (E) and (F) Activation of p38 and phosphorylation of downstream substrates in th
DR α (panel (E)) and DRβ (panel (F)) hearts. In the immunoblots below Tp38 is total p38,
shock protein (on Ser82) and pTAB1 phosphorylated TAB1 (on Ser423). Panels (D) and (F
downstream phosphorylation of HSP27, a substrate of mitogen-activated protein kinase activ
The phosphorylation of these downstream substrates is still present in DRα hearts exposed
each lane is from a different heart. The ﬁgures below each band represent quantiﬁcation of ba
$Pb0.05 PC vs. PC+SB; #Pb0.05 Cont vs. PC+SB.The ﬁndings of our study suggest that it will not be possible to
avoid interfering with the beneﬁcial effects of p38 activation by
selectively inhibiting p38α. Instead attention needs to focus on the
circumstance speciﬁc components of this pathway that lie upstream
and downstream of this key isoform.Acknowledgments
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